Document Detail


The renin inhibitor aliskiren as novel treatment for cardiovascular disease.
MedLine Citation:
PMID:  18221088     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The renin-angiotensin aldosterone system (RAAS) plays a key role in the regulation of blood pressure, acting via the effects of the hormone angiotensin (Ang) II. Ang II increases blood pressure and can exert growth-promoting effects leading to end-organ damage. Excess RAAS activity has been shown to be a major underlying cause of hypertension, heart failure, and related cardiovascular disorders. Inhibitors of renin block the RAAS at its first and rate-limiting step and thus appear to offer an excellent opportunity for blood pressure control. In the past two decades various potential renin inhibitors have been developed but have not been clinically useful. This review discusses a recent patent in the development of a novel class of non-peptide renin inhibitors: an alkanecarboxamide, aliskiren (SPP-100; Novartis). Aliskiren is effective in animal models, while recent results from studies in humans indicate that aliskiren is the first in a new class of orally effective renin inhibitors for the treatment of hypertension.
Authors:
Anabelle O Saez; Thomas Philipp; Jens Nürnberger
Related Documents :
18690518 - Renin-angiotensin system and stroke.
2015168 - Arterial vasodilating profile and biological effects of pinacidil in healthy volunteers.
7041238 - Mechanism of renin release during renal nerve stimulation in dogs.
7034938 - Circulatory and renin responses in man to unilateral reduction of the renal perfusion p...
1632938 - Left ventricular mass as a measure of preclinical hypertensive disease.
16002778 - Heart rate variability and spontaneous baroreflex sequences in supine healthy volunteer...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Recent patents on cardiovascular drug discovery     Volume:  1     ISSN:  1574-8901     ISO Abbreviation:  Recent Pat Cardiovasc Drug Discov     Publication Date:  2006 Nov 
Date Detail:
Created Date:  2008-01-28     Completed Date:  2008-02-15     Revised Date:  2011-11-22    
Medline Journal Info:
Nlm Unique ID:  101263805     Medline TA:  Recent Pat Cardiovasc Drug Discov     Country:  United Arab Emirates    
Other Details:
Languages:  eng     Pagination:  233-40     Citation Subset:  IM    
Affiliation:
Department of Nephrology and Hypertension, University Hospital Essen, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aldosterone Antagonists / therapeutic use
Amides / pharmacology,  therapeutic use*
Angiotensin II Type 1 Receptor Blockers / therapeutic use
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Animals
Antihypertensive Agents / therapeutic use*
Blood Pressure
Drug Therapy, Combination
Fumarates / pharmacology,  therapeutic use*
Humans
Hypertension / drug therapy*
Renin / antagonists & inhibitors*
Renin-Angiotensin System / drug effects,  physiology
Chemical
Reg. No./Substance:
0/Aldosterone Antagonists; 0/Amides; 0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Fumarates; 0/aliskiren; EC 3.4.23.15/Renin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Fibroblast growth factors, fibroblast growth factor receptors, diseases, and drugs.
Next Document:  TP receptor as a therapeutic target in atherosclerosis and related cardiovascular diseases.